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Morphine and its congener opioids are the main therapy for severe pain in cancer. However, chronic morphine treatment stimulates
angiogenesis and tumour growth in mice. We examined if celecoxib (a cyclooxygenase-2 (COX-2) inhibitor) prevents morphine-
induced tumour growth without compromising analgesia. The effect of chronic treatment with celecoxib (by gavage) and/or
morphine (subcutaneously), or PBS on tumour prostaglandin E2 (PGE2), COX-2, angiogenesis, tumour growth, metastasis, pain
behaviour and survival was determined in a highly invasive SCK breast cancer model in A/J mice. Two weeks of chronic morphine
treatment at clinically relevant doses stimulates COX-2 and PGE2 (4.5-fold compared to vehicle alone) and angiogenesis in breast
tumours in mice. This is accompanied by increased tumour weight (B35%) and increased metastasis and reduced survival. Co-
administration of celecoxib prevents these morphine-induced effects. In addition, morphine and celecoxib together provided better
analgesia than either agent alone. Celecoxib prevents morphine-induced stimulation of COX-2, PGE2, angiogenesis, tumour growth,
metastasis and mortality without compromising analgesia in a murine breast cancer model. In fact, the combination provided
significantly better analgesia than with morphine or celecoxib alone. Clinical trials of this combination for analgesia in chronic and
severe pain in cancer are warranted.
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Opioids are the mainstay of treatment for severe pain in advanced
cancer, including metastatic breast cancer (Levy, 1996; Mantyh,
2006). Although opioids act directly on the central nervous system
to relieve pain, their activities on peripheral tissues are responsible
for many of the secondary complications associated with the
management of cancer pain. A recently recognised peripheral
effect of opioids and their receptors is the promotion of
angiogenesis-dependent tumour growth. Opioids at physiologically
relevant concentrations promote angiogenesis in vitro, and in
breast cancer and wound healing in rodents (Gupta et al, 2002;
Poonawala et al, 2005; Singleton et al, 2006). Although naloxone
and naltrexone can inhibit tumour growth in rodents (Zagon and
McLaughlin, 1983a; Koo et al, 1996; Gupta et al, 2002), opioid
receptor antagonists cannot be used to counteract the unwanted
effects of opioids without also compromising analgesia in the
clinical setting. Therefore, it is important to identify agents that
spare the analgesic effect of opioids while inhibiting their
angiogenic effect.
One key mechanism of morphine-induced angiogenesis is nitric
oxide (NO)-dependent MAPK phosphorylation and endothelial
proliferation (Gupta et al, 2002; Poonawala et al, 2005). Morphine
stimulates NO in endothelium and chronic morphine treatment
increases NO synthase (NOS), NO and cyclooxygenase-2 (COX-2)
in mouse kidney (Stefano et al, 1995; Arerangaiah et al, 2007).
Nitric oxide stimulates the enzymatic activity of COX (Salvemini
et al, 1993), and activated COX in turn increases prostaglandin E2
(PGE2) production (Salvemini et al, 1993, 1994; Nedelec et al, 2001;
Birnbaum et al, 2005). Prostaglandin E2 promotes angiogenesis
and tumour progression, and blockade of COX-2 activity inhibits
angiogenesis and tumour progression (Griffin et al, 2002; Leahy
et al, 2002; Chang et al, 2004). On the other hand, prostaglandins
are also implicated in processing pain (Malmberg and Yaksh, 1992;
Julius and Basbaum, 2001; Samad et al, 2001). Indeed, COX-2
inhibitors inhibit the development of morphine tolerance (Wong
et al, 2000).
It is likely that the products of COX-2 such as PGE2 produced in
tumour cells act on the tumour endothelium and promote
angiogenesis. Therefore, morphine-induced tumour growth may
in part be due to the upregulation of COX-2. We hypothesised that
the prolonged use of opioids in cancer stimulates COX-2 and
PGE2, leading to angiogenesis-dependent tumour progression and
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smetastasis and mortality. This raises the possibility that highly
selective COX-2 inhibitors such as celecoxib may block morphine-
induced angiogenesis and tumour growth without compromising
analgesia. We examined the effects of celecoxib on opioid-induced
COX-2 expression, pain, angiogenesis, tumour progression,
metastasis and survival in a murine breast cancer model. We
demonstrate that celecoxib prevents opioid-induced tumour
progression and metastasis and promotes survival, apparently
without impairing the analgesic effect of opioids.
MATERIALS AND METHODS
Animals
Eight- to twelve-week-old A/J mice (The Jackson Laboratory, Ann
Harbor, ME, USA) were maintained under controlled environ-
mental conditions (12-h light to dark cycle, at 231C) in our
AAALAC-accredited facility and provided with standard labora-
tory food and water ad libitum. All experiments were performed
according to the protocols approved by the Institutional Animal
Care and Use Committee (IACUC) at the University of Minnesota.
Mice were euthanised using compressed CO2 from the gas
cylinders at the conclusion of the duration of the treatment and/
or if they appeared moribund (unable to reach food and water and
impaired mobility).
Drugs and chemicals
Pharmacological-grade morphine (Baxter Esilerderle Mfd. Health-
care Corporation, Cherry Hill, NJ, USA), and Celecoxib (celecoxib
capsules, Pfizer Inc., New York, NY, USA) were used. All other
chemicals were obtained from Sigma Chemicals (St Louis, MO,
USA), and cell culture reagents were obtained from Invitrogen
unless otherwise mentioned.
Tumour model
SCK mammary carcinoma was generated in rodents using breast
cancer cells derived from a tumour that spontaneously arose in a
female A/J mouse (Jackson Laboratories) in our laboratory (Griffin
et al, 2002). These tumours grow to B1000mm
3 in 12 days, and
they are highly vascular, invasive and metastasise to the lungs,
resulting in the death of the animals starting at about 15 days after
tumour-cell injection. SCK tumour cells (2 10
5) in 0.05ml of
serum-free medium were injected subcutaneously into the right
hind thigh of A/J mice. Palpable and measurable tumours appeared
4–5 days after injection.
Treatment groups
Tumour-bearing mice were randomly assigned to experimental
groups 1 day after tumour cell injection. Treatments for each
experiment were administered twice daily.
Protocol I To examine the effect of celecoxib on tumour PGE2,
angiogenesis, tumour growth and survival, mice were equally
divided into four groups of (a) normal saline s.c. at 50ml and 0.5%
methylcellulose at 100ml by gavage (control); (b) morphine
sulphate s.c. at 0.714mg per kg per mouse per day for 7 days
and 1mg per kg per mouse per day thereafter (equivalent to 50 and
75mg of morphine per day for a 70kg human, respectively) and
0.5% methylcellulose at 100ml by gavage to ensure similar
administration of vehicle in each animal; (c) celecoxib at 30mg
per kg per mouse by gavage in 0.5% methylcellulose and (d)
morphine sulphate plus celecoxib as described in b and c.
Protocol II To determine the effect of high-dose celecoxib, mice
were treated with (a) normal saline s.c. at 50ml and 0.5%
methylcellulose at 100ml by gavage; (b) morphine sulphate s.c. at
0.714mg per kg per mouse per day for 7 days and 1mg per kg per
mouse per day thereafter; (c) celecoxib at 100mg per kg per mouse
by gavage in 0.5% methylcellulose and (d) morphine sulphate plus
celecoxib as described in IIb and IIc.
Tumour neovascularisation
Tumour cryosections were immunostained with the endothelial
cell marker anti-CD31-PE (1:50 dilution; Pharmingen, San Diego,
CA, USA) and the nuclear stain DAPI (Molecular Probes, Eugene,
OR, USA), as described previously (Poonawala et al, 2005). Three
different sections of tumour were selected for image analysis, and
digital images of at least three different areas of each section were
binarised and linearized to quantify total PE-positive pixels in each
image as a measure of such angiogenic parameters as blood vessel
length, ends and nodes, using the Image Processing Tool kit, Plug-in
Functions for Adobe PhotoShop (Reindeer Games, Asheville, NC,
USA), as described before (Gupta et al, 2002).
Behavioral analysis
Thermal escape latency Tumour-bearing mice were acclimated
on the glass surface of the chamber of the Paw Thermal Stimulator
System (UCSD, San Diego, CA, USA) for 60min before the test
(Hargreaves et al, 1988). A radiant heat stimulus was applied to the
plantar surface of a single hind paw from underneath the glass
floor with a projector lamp bulb (CXL/CXR, 8V, 50W). Paw
withdrawal latency (PWL) to the nearest 0.1s was automatically
recorded when a mouse withdrew its paw from the stimulus.
Stimulus intensity was adjusted to derive an average baseline PWL
of approximately 10.0s in PBS-treated control mice. A 20-s
stimulus cutoff was used to prevent tissue damage.
Western blot analysis
Whole tumour lysates containing 50mg of protein were resolved on
3–15% gradient SDS-PAGE gels, followed by transfer to the PVDF
membrane (Immobilion, Millipore, Bedford, MA, USA). Mem-
branes were blocked for 1h at room temperature in 5% non-fat dry
milk in Tris-buffered saline with 0.1% Tween 20, and incubated
with 1:500 dilution of anti-COX-2 antibody (Cayman Chemical,
Ann Arbor, MI, USA) or anti-b-actin (Santa Cruz Biotechnology
Inc., Santa Cruz, CA) at 41C overnight. After washing, membranes
were incubated with 21 species-specific antibodies conjugated to
alkaline phosphatase for 45min at room temperature. Proteins
were visualised with an ECF Western blotting system (Amersham
Life Sciences, Buckinghamshire, UK). Chemiluminescent signals
were acquired using a Storm 860 PhosphorImager (Molecular
Dynamics, Sunnyvale, CA, USA).
RT-PCR
Total RNA was isolated from tumours using Trizol reagent
(Farooqui et al, 2006). Five micrograms of total RNA was reverse
transcribed using a First-Strand Synthesis System (Invitrogen,
Carlsbad, CA, USA). PCRs were performed by using Taq DNA
polymerase (Continental Lab Products, San Diego, CA, USA).
Sequences of primers homologous to the coding region of mouse
COX-2 (GenBank acc. no. NM_011198) were 50-ACTCACTCAGTT
TGTTGAGTCATT-30 (sense nucleotides 1312–1335) and 50-TTT
GATTAGTACTGTAGGGTTAAT-30 (antisense nucleotides
1871–1894); sequences for mouse GAPDH (GenBank acc. no.
NM_001001303) were: 50-CGTCTTCACCACCATGGAGA-30 (sense
nucleotides 353–371) and 50-CGGCCATCACGCCACAGTTT-30
(antisense nucleotides 635–651) (Lim et al, 2006). Amplification
was performed for 30 cycles at 941C for 50s, 561C for 50s and 721C
for 50s with a final extension cycle for 10min at 721C in a PTC-100
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sthermocycler (MJ Research, Waltham, MA, USA). DNA samples
were separated by electrophoresis in 2% agarose gel. The purified
PCR products obtained were sequenced (Microchemical Facility,
University of Minnesota) to verify that they matched the expected
DNA sequences.
Prostaglandin E2 assay
Prostaglandin E2 levels were estimated in whole tumour lysates
using an EIA Kit (Cayman Chemical Company, Ann Arbor, MI,
USA) as per the manufacturer’s instructions. Lysates were purified
using acetone precipitation of proteins, and supernatants from
each sample were quantified using two different dilutions of each.
In this method, the intensity of the colour produced is measured at
412nm and is inversely proportional to the amount of PGE2
present in the well. Recovery of PGE2 was calculated based on the
recovery of a cold spike of PGE2 added to the lysis buffer and
processed in parallel with tumour lysates. Prostaglandin E2 content
was calculated using a calibration curve prepared with 10–1000pg
per ml of PGE2.
Histology
Lungs were fixed in 10% formalin overnight, and paraffin-
embedded lung sections were stained with haematoxylin and
eosin. Metastatic foci were visualised in a double-blinded manner
using a light microscope.
Statistical analysis
Duration of survival in the four treatment groups was analysed
with Kaplan–Meier curves. Equality of survival curves was
assessed using the Wilcoxon’s log-rank test, which weights
differences in the curves by the number of surviving mice (Klein
and Moeschberger, 1997).
Tumour weight was analysed with an ANOVA model, and
pairwise comparisons among the four treatment groups were made
using Tukey’s studentised range test (HSD) (Christensen, 2002).
Four measures of vascular complexity (pixels, nodes, ends and
line length) were performed at three sites in three mice from each
treatment group. Mice were randomly selected from among those
living at the end of 14 days. Differences between treatment groups
of these measurements were assessed using an ANOVA model with
a random intercept for each mouse to account for within-mouse
correlation of measurements. Tests for treatment group effects
used the between-within method for determining the degrees of
freedom and maximum likelihood to fit the model (Fitzmaurice
et al, 2004).
We assessed longitudinal changes in pain using a repeated-
measures ANOVA model. The model includes three fixed-effect
terms of treatment group, day, and treatment group by day
interaction. It also includes a random-effect term for the mouse-
specific baseline. Tests for treatment group effects at each day used
the between-within method for determining the degrees of
freedom and maximum likelihood to fit the model.
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Figure 1 Cyclooxygenase-2 expression and PGE2 concentration in breast tumours of mice after 13 days of treatment (or 14 days after tumour cell
injection) with morphine and co-administration with celecoxib. (A) Western blot showing upregulation of COX-2 protein in the region of 72–74kDa,
whereas b-actin is shown as a loading control. The arbitrary densitometric units above the bands show the ratio of COX-2 to b-actin. (B) RT-PCR, showing
an upregulation in COX-2 gene expression in the expected region of 583bp. Bands on the bottom show the equal loading of RNA represented by GAPDH.
Arbitrary numeric units show the ratio of COX-2 to GAPDH expression. (C) Prostaglandin E2 concentration is significantly increased in tumours of mice
treated with morphine. Data are shown as mean±s.d. n¼3–5 experiments per observation/data shown. (D) Immunofluorescent staining of tumour
cryosections using anti-CD31 PE (red), an endothelial cell marker and anti-COX-2 followed by a 21 Ab conjugated with FITC (green). The overlaid image in
the right hand panel shows yellow staining due to increased COX-2 in the endothelium in morphine-treated mice. Larger number of non-endothelial cells
show COX-2 expression (green) in middle and overlaid panel after morphine treatment. Magnification,  600.
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sRESULTS
Morphine upregulates COX-2 expression and PGE2 in
tumours
To determine whether morphine treatment exaggerates the
expression of COX-2, we evaluated COX-2 protein and mRNA
expression in SCK mammary tumours in A/J mice after 13 days of
treatment using Protocol I. Cyclooxygenase-2 protein and mRNA
levels were increased by five- to seven-fold after morphine
treatment as compared to PBS-treated mice (Figure 1A and B).
Upregulation of COX-2 expression was higher in endothelial and
tumour cells in morphine-treated mice compared to PBS-treated
controls, based on immunofluorescent staining of tumour
cryosections (Figure 1C). Notably, morphine induced a much
stronger expression of COX-2 in tumour cells than in endothelial
cells. The upregulation of COX-2 protein and gene expression was
accompanied by an B5-fold increase in PGE2 (Po0.05 vs control)
in tumours of mice treated with morphine (Figure 1D). Co-
administration of celecoxib blocked this morphine-induced
increase in COX-2 expression and PGE2.
Celecoxib inhibits morphine-induced tumour angiogenesis
We next examined the effect of combined treatment with morphine
and celecoxib on tumour angiogenesis in tumour-bearing mice.
Immunostained sections of SCK tumours from mice treated with
morphine for 2 weeks showed an increase in angiogenesis
(Figure 2A). Tumours in morphine-treated mice appeared to have
A
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Figure 2 Effect of morphine and co-administration with celecoxib on tumour angiogenesis and tumour growth, after 13 days of treatment. (A). Tumour
cryosections were stained with endothelial cell-specific anti-CD31 PE (red) and nuclear stain, DAPI (blue). The red and blue images of the same area are
overlaid to show the tumour vasculature in red and cellular presence represented by blue nuclei. Note the dense, heavily branched and wide blood vessels
distributed uniformly in tumours from morphine group. Celecoxib-treated mouse tumours exhibit fewer and collapsing blood vessels and areas with week
CD31 staining suggesting degenerating vasculature. This week CD31 staining is accompanied by bald areas without any blue nuclei. However, celecoxib
given with morphine did not result in degenerating looking vessels, even though the blood vessels were fewer, less dilated, smaller and accompanied by bald
areas devoid of blue nuclei compared to morphine-alone-treated mice. Magnification,  150. Each figure represents nine sections from three different
mouse tumours. (B) Quantitative expression of vasculature in tumour sections is shown as PE-positive pixels (representing red staining for blood vessels),
number of nodes (equivalent to branch points), vessel ends (for the number of vessels) and line length (vessel length). Each point is the mean±s.d. of nine
observations from three different mouse tumours. (C) Weight of tumours from mice that survived until day 14. Note, morphine treatment increased
tumour growth significantly, whereas celecoxib inhibited morphine-induced increase in tumour weight. n¼6–18 tumours.
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sa higher density of dilated and branching vessels as compared to
PBS-treated controls. In contrast, tumours from mice treated with
both celecoxib and morphine appeared to have a lower vessel density
with unevenly distributed and thinner vessels, among which were
interspersed hollow spaces suggestive of the absence of endothelial
and tumour cells in these areas. Similarly, tumours in mice treated
with celecoxib alone had small, stringy vessels with large unstained
areas suggestive of the absence of endothelial and tumour cells.
These qualitative observations of immunostained tumour sections
were corroborated by quantitative morphometric analysis
(Figure 2B). We observed increased microvessel density (CD31-PE-
positive pixels, 1.4-fold), vessel number (ends, 1.9-fold), total length
(1.4-fold) and branching (nodes, 2.2-fold) in morphine-treated mice
as compared to PBS-treated controls (P¼0.001 vs control for all
values). Combined treatment of celecoxib with morphine signifi-
cantly reduced all angiogenic parameters as compared to morphine
by itself. Tumours in the celecoxib-treated group had lowered vessel
density, number, length and branching as compared to controls, but
there was no statistically significant difference. Taken together, these
data suggest that morphine stimulates tumour angiogenesis in SCK
tumours similar to that shown for MCF7 human tumours in nude
mice (Gupta et al, 2002), whereas celecoxib inhibits morphine-
induced angiogenesis. Importantly, celecoxib blocked morphine-
induced neovascularisation in these tumours, suggesting that COX-2
plays a critical role in the tumour-promoting activity of morphine.
Celecoxib inhibits morphine-induced tumour growth and
metastasis
We next evaluated the effect of morphine and celecoxib on tumour
growth in tumour-bearing mice. After 13 days of treatment with
morphine, mean tumour weight in morphine-treated mice was
1.35g compared to 0.95g in PBS-treated controls (Po0.001;
Figure 2C). Celecoxib significantly reduced morphine-induced
tumour growth resulting in a mean tumour weight of 0.69g
compared to PBS-treated controls (Po0.001). Furthermore,
celecoxib-treated mice showed no significant difference in their
tumour weights as compared to PBS-treated controls after 13 days
of treatment with celecoxib. Interestingly, tumours in morphine
and celecoxib co-administered mice were significantly smaller than
PBS-treated mice (Po0.001).
Increased angiogenesis and tumour growth after 13 days of
morphine treatment was accompanied by increased metastasis
(Table 1). A significant number of mice died on day 14 due to the
invasiveness of this tumour model (discussed below). Therefore,
we examined metastases in the lungs of mice that died on day 14
and the remaining mice that were alive after euthanasia. One
hundred percent of morphine-treated mice showed metastatic foci
in the lungs as compared to only 70% of control mice with lung
metastases (Table 1). Lungs recovered from dead mice showed
metastases in all groups except celecoxib. Of the surviving mice,
100% of morphine-treated mice showed lung metastases as
compared to only 57% of PBS-treated mice. In contrast, celecoxib
alone or co-administered with morphine showed metastasis in
only 30 or 25% surviving mice, respectively. From these data, it
appears that celecoxib prevents metastases in this model and also
that induced by morphine.
Celecoxib plus morphine increases survival
We examined the effect of morphine and celecoxib on survival in
tumour-bearing mice. Treatments were started 1 day after tumour
cell injection and continued for 14 days. The day of death
represents the number of days after the initiation of treatments.
Morphine-treated mice had the worse survival rate with 70% dying
by day 14 as compared to 30% of PBS-treated controls (Figure 3A).
Only 20% of mice treated with morphine plus celecoxib had died
by day 14, with only one death occurring by day 13. Surprisingly,
20% of mice treated with celecoxib died as early as day 4 and 40%
had died by day 9, while the remainder of the mice survived until
day 13 and 50% had died by day 14.
In the SCK tumour model, tumours at day 4 are barely palpable
and non-metastatic. Therefore, the early death of mice after
celecoxib treatment is not due to cancer progression. Several
studies on rodents have used celecoxib in the range 30–250mg per
kg per mouse for several days to weeks (Koki and Masferrer, 2002;
Table 1 Presentation of lung metastasis on day 14 after tumour cell
injection
Dead mice Live mice Total (dead+live)
PBS 6/6 8/14 14/20 70%
Morphine 12/12 6/6 18/18 100%
Celecoxib 0/2 3/10 3/12 25%
Celecoxib+morphine 2/2 4/16 6/18 33%
Metastasis was examined in the H&E stained lung sections of mice that died on day
14 and in the lungs of mice remaining alive. Data are expressed as number of mice
with lung metastasis/number of mice in the specific treatment group on day 14 (alive
and/or dead).
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Figure 3 Effect of morphine and co-administration of celecoxib on survival and pain behaviour in SCK tumour-bearing mice. (A) Kaplan–Meier plot for
survival of SCK tumour-bearing mice after treatment with morphine and co-administration with celecoxib for 13 days (after 14 days of tumour cell injection).
Note, celecoxib alone led to mortality starting at day 4, whereas morphine treatment resulted in highest mortality, which occurred on day 14. Co-
administration of both showed highest percent of surviving mice on day 14. n¼20 mice/treatment. (B) Behavioural analysis performed for thermal
hyperalgesia using Hargreave’s apparatus. Right paw of the tumour-bearing leg was tested on each mouse three times at 10min intervals for PWL. Decrease
in duration of heat tolerance shows an increase in thermal perception of pain. Overall, pain increases with time during tumour growth in control as wella s
morphine- or celecoxib-treated mice. Co-administration of morphine and celecoxib shows the highest heat tolerance or least perception of thermal stimuli.
Data are shown as mean±s.d. n¼6–20.
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sLeahy et al, 2002). None of these studies reported toxicity or
adverse effects of these COX-2 inhibitors on the survival of mice.
The only difference between our study and others is that our study
used A/J mice and a SCK tumour model. It is possible that A/J mice
are more sensitive to COX-2 toxicity.
To address the toxicity induced by celecoxib, we performed the
same survival experiments in tumour-bearing mice with an
increased initial dose of celecoxib 100mg per kg per day on day
1 per protocol II. Surprisingly, 5 out of 10 mice receiving 100mg
per kg of celecoxib died within 24h, and the other 5 appeared
moribund (Table 2). After unsuccessful attempts to revive them,
the remaining mice were euthanised after 48h. However, mice that
were co-administered morphine with 100mg per kg of celecoxib
did not show any signs of toxicity and appeared to have the same
levels of activity as morphine-treated mice after 24h. After the first
day, the dose of celecoxib was reduced to 30mg per kg per day
with continued administration of 1mg per kg per day morphine,
and by day 10 of treatment (11 days after tumour cell injection),
100% of the mice were still alive. Thus, celecoxib alone impaired
survival via non-cancer-related mechanisms. In contrast, mor-
phine at higher doses was not toxic but still impaired survival at
later stages by exaggerating tumour growth and metastasis. When
administered together even at higher doses, morphine and
celecoxib blocked the adverse effect of the other, resulting in
increased survival. Taken together, these data show that a
combination of morphine and celecoxib increases the survival
rate of tumour-bearing mice as compared to treatment with either
morphine or celecoxib alone, which is consistent with our findings
that combination treatment also decreases angiogenesis and
tumour burden.
Effect of celecoxib on morphine-induced analgesia
Treatment effects on pain were tested using the PWL of the
tumour-bearing leg, using a modified Hargreaves device. Baseline
PWL was determined on day 0 before starting the treatments and
24h after injecting the tumour cells. This time was chosen to avoid
recording effects of pain due to the injection procedure and
inflammation that could occur immediately after injection. Mice
had no signs of swelling, inflammation or impaired mobility 24h
after tumour-cell injections. Baseline PWLs were the same for all
treatment groups. Paw withdrawal latencies were significantly
decreased in mice after 5 days of treatments (or 6 days after
tumour-cell injection) with PBS and celecoxib (Po0.0001 vs
baseline at day 0); both groups had palpable and measurable
tumours on day 5. Morphine alone had an anti-nociceptive effect
after 5 days of treatment (Po0.003 vs PBS-treated control), but
had no effect after 10 and 14 days of treatment as compared to
controls. In contrast to the effect of celecoxib or morphine alone,
the co-administration of both resulted into a continuous analgesic
effect for the entire 14 days of treatment. Paw withdrawal latencies
in this group were no different than the baseline throughout the
14-day period. The duration of heat tolerance was significantly
higher when both drugs were co-administered as compared to the
effect of all other treatment groups (Po0.0001 on days 10 and 14
for morphineþcelecoxib vs morphine or celecoxib or control).
Although celecoxib treatment resulted in decreased latency vs
control on day 10 (Po0.003), there was no statistically significant
difference between morphine and control on day 10. On day 14,
PWLs decreased further after morphine or control treatment as
compared to day 10, and were no different than celecoxib
treatment on day 14. Injections during the course of treatment
for all groups did not result in any noticeable abnormal behaviour.
DISCUSSION
Our study provides a proof of principle that the chronic use of
opioids stimulates COX-2, leading to increased prostaglandin(s),
impaired analgesia and increased tumour angiogenesis, growth,
metastasis and mortality. We show that inhibition of COX-2 by co-
administration of celecoxib prevents morphine-induced tumour
growth and metastases and increases survival. Furthermore, co-
administration of celecoxib with morphine provides analgesia even
after 14 days of treatment, suggesting that celecoxib may have a
salutary effect on opioid analgesia. Cyclooxygenase-2 inhibition
may at least partly explain the clinical improvements in post-
operative pain control that have been seen with a combination of
opioids and COX-2 inhibitors and/or NSAIDs (Kroin et al, 2002;
Malan et al, 2003).
Chronic administration of opioids has been linked to angio-
genesis, progression of tumour growth and hyperalgesia. Tolerance
to the analgesic effect of opioids is believed to be mediated at least
partly by prostaglandin-mediated mechanisms (Powell et al, 1999).
Intrathecal administration of COX-2 inhibitors attenuates the
development of tolerance to morphine (Wong et al, 2000). Further,
intrathecally administered COX-2 inhibitors have significant
analgesic activity in hyperalgesic states not associated with
inflammation, possibly by modulation of COX-2 that is constitu-
tively expressed in the spinal cord (Svensson and Yaksh, 2002).
Increased PGE2 leads to thermal hyperalgesia in the spinal cord
following intrathecal delivery of protease-activated receptor
(PAR)-derived peptide (Koetzner et al, 2004). Although the
mechanisms of morphine and PAR-induced activation of PGE2
may be different, it appears that PGE2 mediates thermal
hyperalgesia, irrespective of the central or peripheral site of
action. Furthermore, inhibition of morphine-induced PGE2 by
celecoxib in tumours is accompanied by prevention of thermal
nociception in morphine-treated mice. It has been suggested
before that nerve injury and TNF-induced pain-related behaviour
is partly dependent upon peripheral prostaglandins (Schafers et al,
2004). Morphine stimulates TNFa secretion both centrally and
peripherally (Gupta and Stephenson, 2007). It is therefore possible
that morphine-induced upregulation of COX-2 and PGE2 may be
due to the elevation of TNFa caused by morphine and/or due to
some other mechanism.
The promotion of tumour growth by morphine appears to be
dependent on PGE2-mediated stimulation of angiogenesis. Morphine-
induced upregulation of COX-2 is critical in the progression of
tumour angiogenesis, because tumour cell-derived COX-2 pro-
foundly influences angiogenesis (Chang et al, 2004). Although
endothelial COX-2 does not appear to be extremely upregulated,
increased COX-2 in non-endothelial cells appears to be responsible
for increased PGE2 in tumours of morphine-treated mice. Koki and
co-workers have proposed that COX-2 is upregulated in tumour
epithelial cells and stroma in response to growth factors leading to
Table 2 Effect of morphine treatment on survival following high-dose
celecoxib treatment
Percent of surviving mice after treatment
Treatment type After day 1 After day 2 After day 10
(i) Vehicle control 100 100 100
(ii) Morphine 100 100 100
(iii) Celecoxib 50 0 —
(iv) Morphine+celecoxib 100 100 100
a
After 24h of SCK tumour cell injection, mice were treated with (a) vehicle control,
50ml normal saline+50ml 0.5% methylcellulose; (b) morphine, 0.714mg per kg
mouse per day (equivalent to 50mg morphine per day per 70kg human adult) during
the first week, followed by 1mg per kg mouse per day, thereafter; (c) 100mg
celecoxib per kg mouse per day for 1 day; and (d) morphine as described in (b) and
celecoxib.
a100mg per kg mouse per day for one day followed by 30mg per kg per
day.
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sincreased production of PGE2 that acts on endothelium and
promotes angiogenesis (Koki and Masferrer, 2002). Similarly,
morphine treatment stimulates COX-2 in non-endothelial cells in
the tumour, which leads to increased PGE2 that then acts on
endothelium to stimulate tumour angiogenesis. It is likely that
celecoxib inhibits COX-2 in tumour cells, resulting in the
inhibition of tumour growth and decreased angiogenesis. There-
fore, celecoxib may inhibit angiogenesis indirectly via inhibition of
tumour growth, rather than directly via anti-angiogenic mechan-
isms. This is further supported by observations of Koki and
Masferrer (2002) that nude mice showed a decline in mammary
tumour growth continuously throughout a 3-week treatment with
celecoxib.
These anti-angiogenic and anti-tumour effect in rodents have
been observed using extremely high doses of celecoxib. However,
survival of mice was not impaired, even though animals were fed
chow supplemented with extremely high amounts of celecoxib
(1600p.p.m.; B250mg per kg per day) (Koki and Masferrer, 2002).
Similarly, Leahy et al (2002) reported that nude mice treated for 40
days with celecoxib (25mg per kg per day) had a significant
reduction in tumour growth of HT-29 and HCT-116 human colon
carcinoma xenografts and a reduction in the proliferation of
microvascular endothelial cells). In the same study, rats implanted
with pellets containing FGF2 in an intrasomal pocket in the cornea
and treated with celecoxib 30mg per kg per day for 4 or 6 days by
gavage showed a significant reduction in corneal neovascularisa-
tion. In contrast to these observations, we found that mice treated
with celecoxib at 30mg per kg per day started dying 4 days after
treatment. After 7 days of treatment, only 60% of the celecoxib-
treated mice survived, whereas 100% of mice were still surviving in
the group treated with celecoxib plus morphine. This early
mortality in the celecoxib-treated group was not due to tumour
growth or metastases. Administration of a higher dose of celecoxib
(100mg per kg per day) resulted in an even higher early mortality
rate (50% within the first 24h). Impaired survival in celecoxib-
treated mice was therefore likely due to drug toxicity. Importantly,
at both the low and high doses, celecoxib co-administered with
morphine did not impair mouse survival. The survival rate in mice
treated with celecoxib plus morphine was comparable to PBS-
treated mice, and this rate was significantly better compared to
morphine-only treatment. We believe that high doses of celecoxib
used by us and others may have nonspecific activity beyond
selectively inhibiting COX-2 activity. We used high doses of
celecoxib, because (a) the studies described above show an
inhibition of angiogenesis with the doses we used and (b) to
examine if morphine could prevent high-dose celecoxib-induced
toxicity. In our study, mice treated with high doses (100mg per kg)
of celecoxib and morphine survived, whereas those treated with a
high dose of celecoxib alone died within 24h of treatment,
suggesting that morphine prevents high-dose celecoxib toxicity.
The loss of mice 13 days after morphine treatment appears to be
related to increased tumour growth and metastasis as compared to
PBS-treated mice. In contrast, mice treated with celecoxib plus
morphine showed significantly reduced tumour growth as
compared to PBS or celecoxib-treated mice. Immunofluorescent
images of tumour sections show appreciably wider vessels in both
groups of mice treated with morphine or morphine plus celecoxib.
As morphine appears to induce tumour vessel dilation, we
speculate that it may facilitate the availability of celecoxib in the
ischaemic tumour. Earlier observations have shown that morphine
induces vasodilatation by stimulating NO (Stefano et al, 1995). In
addition, recent observations from our laboratory show that 3
weeks of morphine treatment stimulates the expression of the
vasodilatory enzymes iNOS, eNOS, COX-2 and HO1 in the kidneys
of C3H mice bearing NCTC 2472 tumours (Arerangaiah et al,
2007). Upregulation of NO by morphine may also compensate
for the vasoconstrictive and hypertensive effect of celecoxib on
cardiovascular haemodynamics. As COX-2 activity and NOS
activity co-stimulate each other, it is likely that inhibition of
COX-2 reduces NO production, resulting in haemodynamic insult.
Addition of morphine may therefore prevent celecoxib toxicity by
activating alternative pathways, including NOS and HO1. Irre-
spective of the mechanism, our data show that co-administration
of celecoxib with morphine reduces tumour metastasis induced by
morphine. Based on these data and supportive observations, we
conclude that celecoxib and morphine may directly and/or
indirectly block each other’s ‘ill effects’. Therefore, although
celecoxib reduces morphine-induced angiogenesis, tumour growth
and metastasis, morphine prevents celecoxib-induced mortality
and both together provide a better analgesic response and
improved survival. It is important to note that co-administration
of celecoxib with morphine resulted in significantly reduced
tumour growth as well as pain relief as compared to control or
celecoxib or morphine alone. Our observations are supported by
another study showing that stress and morphine together reduced
survival of rats bearing MAT13762B mammary ascites tumour,
which was reversed by naltrexone, suggesting an opiate receptor-
mediated mechanism and reduced NK cell activity (Lewis et al,
1983, 1984). Thus, improved survival in mice treated with a
combination of morphine and celecoxib may be due to better
analgesia in addition to the inhibition of angiogenesis and tumour
growth.
Although our study shows that clinically relevant doses of
morphine stimulate tumour angiogenesis and tumour growth and
lead to reduced survival, some past studies have observed
conflicting effects of morphine on angiogenesis and tumour
growth. We believe that these differences are primarily due to
the extremely high cytotoxic doses of morphine given in these
studies as compared to clinically and physiologically relevant and
opioid receptor-specific doses that ought to be administered.
Ishikawa et al (1993) showed that 10mg per kg morphine increases
EL-4 leukaemia in C57/BL6 mice and Sarcoma 180 carcinoma in
ddY mice in tumour growth in mice after 10 days of treatment.
In this systematically performed investigation, morphine did not
stimulate the growth of EL-4, P388, MM-46 or Meth-A cells in
vitro. These data are in agreement with our earlier studies showing
that morphine does not have any effect on MCF-7 human breast
cancer cell proliferation (Farooqui et al, 2006) and that morphine
stimulates MCF-7 breast tumour growth by promoting angio-
genesis (Gupta et al, 2002). Morphine can affect tumour growth by
(a) directly acting on the tumour cells, (b) by directly acting on the
endothelial cells and (c) by acting on the central nervous system-
mediated secretion of cytokines and growth factors that may alter
the tumour microenvironment (Gupta and Stephenson, 2007).
Morphine acts on the endothelium in a paracrine manner by
increasing COX-2 activity in the tumour cells that in turn promotes
tumour angiogenesis by increased PGE2. Therefore, morphine by
itself does not modulate tumour cell growth in culture but, due to
upregulation of COX-2 in tumour cells, stimulates angiogenesis
in vivo, resulting in increased tumour growth and metastasis.
These observations suggest that in vivo examination may be more
relevant than studying the effect of morphine on isolated cells.
Conversely, some studies suggest an inhibitory effect of
morphine on tumour growth. A high dose of morphine was
shown to inhibit tumour growth and lung metastasis in a model of
cancer pain in B16-BL6 melanoma cell growth in C57/BL6 mice,
and to inhibit the adhesion, invasion and metastasis of colon
cancer cells in vitro (Harimaya et al, 2002; Sasamura et al, 2002).
Similarly, another study showed that high doses of morphine (up
to 30mg per kg) as well as naloxone inhibit MCF-7 breast cancer
after d22 and MDA MB231 breast cancer progression after d14 in
nude mice (last periods of observation) (Tegeder et al, 2003).
However, the doses of morphine used in this study are not
clinically relevant because humans suffering from cancer are
administered far lower doses of morphine than those required
for analgesia in rodents. Moreover, in MCF7 tumour model,
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smeasurable tumour growth is observed only after 2 weeks of
tumour cell xenografts and differences between treatments are
observed after 3 weeks of treatment, but the study was concluded
on day 22. Thus, the use of clinically toxic doses of morphine in
this study, as well as its early conclusion, may account for the
observed inhibition of tumour growth.
Our observation of morphine-induced tumour growth is
supported by earlier studies showing an inhibition of tumour
growth in rodents with low dose of the OR antagonists naloxone
and naltrexone, but not with higher dose (Zagon and McLaughlin,
1983a,b). At low doses, naloxone antagonizes OR activity, but at
higher doses, it may have nonspecific effects. More recently, the
OR antagonists naloxone and naltrexone were shown to inhibit
breast cancer growth in mice and rats, respectively (Koo et al,
1996; Tegeder et al, 2003). These data suggest that tumour
progression may be mediated by endogenous opioids and opioids
receptors acting directly on tumour cells or endothelial cells, or by
other paracrine and centrally mediated mechanisms.
Some studies have demonstrated inhibition of angiogenesis by
high doses of morphine and b-endorphin in a CAM assay (Pasi
et al, 1991). However, these results may be due to the nonspecific
activity of excessive morphine dosage, and the difference in OR
presentation in the embryonic vs tumour endothelium. OR activity
is believed to be upregulated in the tumour endothelium because
of the high concentrations of pro-inflammatory cytokines and
growth factors in the tumour microenvironment. Indeed, these
cytokines and growth factors are known to upregulate the
expression of ORs in several cell types (Gupta chapter endothe-
lium, 2007), and growth factors such as VEGF have been shown to
upregulate MOR expression in endothelial cells (Chen et al, 2006).
As such, we believe that these findings do not contradict our
hypothesis or results, but rather point to the complications of
using morphine at excessive doses and in environments dissimilar
to the tumour endothelium.
Our observations are in agreement with a study by Singleton
et al (2006) that observed morphine-induced angiogenesis, using
physiologically relevant doses of morphine. The authors showed
that clinically relevant doses of morphine and MOR-specific
agonist DAMGO stimulate angiogenesis by transactivating
VEGFR2. The MOR-specific antagonist MNTX antagonized
morphine-induced angiogenesis. Taken together, these observa-
tions suggest that excessive doses of morphine may inhibit
angiogenesis because of their nonspecific cytotoxicity, whereas
physiologically relevant doses stimulate angiogenesis via OR-
mediated activity.
In conclusion, pain is closely linked to disease progression and
metastasis in cancer. Therefore, finding suitable strategies to
combat both without having a deleterious effect on one or the
other is necessary in order to provide maximum benefit to the
patient, resulting in better quality of life and improved survival.
Considering that opioids are the only choice of treatment for
severe pain, the addition of celecoxib to cancer-related pain
management regimens may improve the analgesic response to
morphine and also prevent morphine-induced angiogenesis,
tumour growth and metastasis. Therefore, the hypothesis that
has been proved in mice in this study warrants human trial to
examine its application in the management of pain in cancer
patients.
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